Stating the obvious: data was supplied to the FDA to support this fast-track status. We know that the enrollment in the trial is proceeding quickly.

Obviously -- there are promising results so far that WE haven't seen but that the people that matter HAVE seen.

I think it's very conservative to think that 150,000 people a year would use Bril-OM if available. It might become routine for all patients with chemo to use it.